Cellarity, a Somerville, Mass.-based drug discovery startup, scored $121 million in Series C funding. Lead investor Flagship Pioneering was joined by Kyowa Kirin, Hanwha Impact Partners and others in the round.
Nested Therapeutics, a Cambridge, Mass.-based precision medicine platform for hard-to-treat cancers, launched with a $90 million Series A round. The Life Sciences Investing business within Goldman Sachs Asset Management led the investment, which saw additional support from Foresite Capital, Avidity Partners, Cowen Healthcare Investments and Section 32.
Alloy Therapeutics Inc., a Waltam, Mass.-based drug discovery platform, closed a $42 million Series D round. Led by 8VC and Mubadala Capital, the investment included participation from Thiel Capital, Presight Capital, Founders Fund and others.
Valitor Inc., a Berkeley, Calif.-based medicine engineering startup, raised $28 million in Series B financing and named Steven Lo to the post of chief executive. Morningside led the round, which included participation from First Spark Ventures, ExSight Ventures, Berkeley Catalyst Fund and Pandect Bioventures. Mr. Lo was previously president and CEO of Zosano Pharma.
Katalyst, a Las Vegas-based maker of a full-body electro muscle stimulation workout product, landed $26 million in Series A funding. Stripes led the round, which included contributions from Incisive Ventures, Unlock Venture Partners and others.
Araris Biotech AG, a Swiss startup developing antibody-drug conjugates, picked up a $24 million investment. Led by 4BIO Capital and Pureos Bioventures, the round included contributions from VI Partners, Schroders Capital, btov Partners, Redalpine, Wille AG and the Institute for Follicular Lymphoma Innovation.
Sibylla Biotech, an Italy-based drug discovery startup, secured €23 million in Series A financing. V-Bio Ventures led the investment, which saw participation from Seroba Life Sciences, 3B Future Health Fund, Claris Ventures, CDP Venture Capital, VI Partners, Indaco Venture Partners and Vertis SGR. Ward Capoen from V-Bio, Bruno Montanari from Seroba, Ciro Spedaliere from Claris Ventures, and Marianne Bjordal from 3B Future Health Fund will join Sibylla’s board.
Vergent Bioscience, a Minneapolis-based startup developing tumor-targeted imaging agents, completed a $21.5 million Series B round led by Orlando Health Ventures. New investors Intuitive Surgical Inc., Windham Venture Partners and Rex Health Ventures also participated in the round, along with previous backers Spring Mountain Capital and Colle Capital.
Biopharmaceutical Research Co., a pharmaceutical cannabis startup, gathered $20 million in Series A funding. Intrinsic Capital Partners led the round, which included support from Argonautic Ventures, Achari Ventures, AFI Capital Partners, Delta Emerald Ventures and others. Osagie Imasogie, senior managing partner at PIPV Capital and founder of GlaxoSmithKline Ventures, joined the company’s board.
Blue-Zone Technologies Ltd., a Toronto-based company whose technology reduces hazardous environmental waste from hospitals, fetched $8 million in funding led by the Canadian venture capital arm of Crédit Mutuel Equity and Round Pound Ventures.
|